ABSK-111

N/A

Report date: 2023/03/30 16:55:51
NME

Base Information

Drug NameABSK-111
Drug Alias NameABSK-111
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitors
TargetsEGFR exon 20 insertion mutations
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesABbisko Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A